Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants
Fiche du document
2016
- handle: 10670/1.6nfp4q
- halshs: halshs-01266374
- doi: 10.1016/j.healthpol.2016.01.005
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.healthpol.2016.01.005
Mots-clés
NITAG Qualitative research Interviews Health policy Vaccination recommendations Human influenza Policy-making I - Health, Education, and Welfare/I.I1 - Health/I.I1.I18 - Government Policy • Regulation • Public HealthSujets proches
Communicable diseases--Vaccination Preventive inoculation Inoculation Preventive inoculation Diseases--VaccinationCiter ce document
Maria-Laura Silva et al., « Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants », HAL-SHS : économie et finance, ID : 10.1016/j.healthpol.2016.01.005
Métriques
Partage / Export
Résumé
Objectives: Target groups for seasonal influenza vaccination are nationally defined based on several factors. However, few studies have explored the policy-making processes at the country-level. We investigated key differences in the policy-making process for the development of vaccination recommendations between France (FR) and The Netherlands (NL). This paper presents preliminary results on the evidence used in the decision-making process and focuses on the interactions between the experts and stakeholders.Methods: A documentary analysis identified the stakeholders of this process as governmental authorities, research institutions, associations, and manufacturers. This qualitative study included at least one expert from each stakeholder group. Thirty-three semi-structured interviews were performed in 2013 (16 FR, 17 NL). We used NVivo10 (R) to perform a thematic content analysis on the data.Results: National Immunization Technical Advisory Groups (NITAGs) were the key stakeholders in the development of recommendations. There was no systematic standard evaluation of evidence during the decision-making process in both countries. Likewise, voting was not systematic, although it did occur more often in FR. A declaration of interests was obligatory in both countries. Experts with no conflicts of interest were rare because many depend on private funding for their research on influenza vaccination.Conclusions: The transparency of the NITAGs' procedures for the development of recommendations should be improved. We believe improvements might be achieved by the systematic standard evaluation of evidence, consistent voting, clear declarations of interest, and increased public funding for vaccination research